FDA compounder NDC directory
Browse every current FDA compounder source row, including records that do not contain a usable NDC.
Compounder NDC directory#
Every current compounder source row is browsable, including records whose FDA source did not provide a usable product, package, or lookup NDC. Browse the unified current auxiliary catalog. · Browse the complete captured source and snapshot history.
| Establishment | FEI | Product NDC | Package NDC | Brand | Nonproprietary name | Active ingredients | Period | Normalization | Source date |
|---|---|---|---|---|---|---|---|---|---|
| Hybrid Pharma | 079665742 | 26436-5609 | 26436-5609-5 | Alprostadil; Papaverine Hydrobromide; Phentolamine Mesylate | 8.3 ug/1 mL; 22.5 mg/1 mL; .83 mg/1 mL | 2025-2 | valid | 2026-08-12 | |
| Hybrid Pharma | 079665742 | 26436-5609 | 26436-5609-5 | Alprostadil; Papaverine Hydrobromide; Phentolamine Mesylate | 8.3 ug/1 mL; 22.5 mg/1 mL; .83 mg/1 mL | 2025-1 | valid | 2026-08-12 | |
| Hybrid Pharma | 26436-5609 | 26436-5609-5 | Trimix 8.3/22.5/0.83 | ALPROSTADIL, PAPAVERINE, PHENTOLAMINE 8.3/22.5/0.83 | 8.3 ug/1 mL; 22.5 mg/1 mL; .83 mg/1 mL | 2025-1 | valid | 2025-09-25 | |
| Hybrid Pharma | 079665742 | 26436-5609 | 26436-5609-5 | Alprostadil; Papaverine Hydrobromide; Phentolamine Mesylate | 8.3 ug/1 mL; 22.5 mg/1 mL; .83 mg/1 mL | 2024-2 | valid | 2026-08-12 | |
| Hybrid Pharma | 26436-5609 | 26436-5609-5 | Trimix 8.3/22.5/0.83 | ALPROSTADIL, PAPAVERINE, PHENTOLAMINE 8.3/22.5/0.83 | 8.3 ug/1 mL; 22.5 mg/1 mL; .83 mg/1 mL | 2024-2 | valid | 2025-09-25 | |
| Hybrid Pharma | 079665742 | 26436-5609 | 26436-5609-5 | Alprostadil; Papaverine Hydrobromide; Phentolamine Mesylate | 8.3 ug/1 mL; 22.5 mg/1 mL; .83 mg/1 mL | 2024-1 | valid | 2026-08-12 | |
| Hybrid Pharma | 26436-5609 | 26436-5609-5 | Trimix 8.3/22.5/0.83 | ALPROSTADIL, PAPAVERINE, PHENTOLAMINE 8.3/22.5/0.83 | 8.3 ug/1 mL; 22.5 mg/1 mL; .83 mg/1 mL | 2024-1 | valid | 2025-09-25 |